Brought to you by 
J&J's Tibotec, Gilead create combination products for HIV
30 Oct 2018
Executive Summary
Johnson & Johnson’s Tibotec Pharmaceuticals Ltd. (infectious diseases) has teamed up with Gilead Sciences Inc. (HIV/AIDS, respiratory, and cardio/metabolic diseases) to create a fixed-dose antiretroviral therapy that combines Tibotec’s Prezista (darunavir) with Gilead’s cobicistat, which increases blood levels of some HIV meds to enable once-daily dosing.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J's Tibotec, Gilead create combination products for HIV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice